David A. Cairns

Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data.

Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data.

Journal: BMJ open

Published: May 11, 2026

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

Journal: British journal of haematology

Published: December 08, 2025

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.

Journal: The New England journal of medicine

Published: December 03, 2025

The density of tumour infiltrating lymphocytes in oesophago-gastric cancer varies with disease stage, geographical region and treatment: a post hoc analysis of nine phase III clinical trials.

The density of tumour infiltrating lymphocytes in oesophago-gastric cancer varies with disease stage, geographical region and treatment: a post hoc analysis of nine phase III clinical trials.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: November 07, 2025

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.

Journal: HemaSphere

Published: June 22, 2025

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: June 16, 2025

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Journal: Blood

Published: May 14, 2025

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 18, 2025

Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis.

Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis.

Journal: Journal of the National Cancer Institute

Published: July 17, 2024

How should overall survival be analysed in randomised clinical trials in cancer if participants receive subsequent treatment lines? A stakeholder consultation.

How should overall survival be analysed in randomised clinical trials in cancer if participants receive subsequent treatment lines? A stakeholder consultation.

Journal: Trials

Published: July 11, 2024

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Haematology

Published: June 21, 2024

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

Journal: Blood cancer journal

Published: May 14, 2024

Showing 1-12 of 104

Last Updated: 09/26/2026